Ocular Expression and Distribution of Products of the POAG-Associated Chromosome 9p21 Gene Region by Chidlow, Glyn et al.
Ocular Expression and Distribution of Products of the
POAG-Associated Chromosome 9p21 Gene Region
Glyn Chidlow1,2., John P. M. Wood1,2*., Shiwani Sharma3, David P. Dimasi3, Kathryn P. Burdon3,
Robert J. Casson1,2, Jamie E. Craig3
1Ophthalmic Research Laboratories, South Australian Institute of Ophthalmology, Hanson Institute Centre for Neurological Diseases, Adelaide, South Australia, Australia,
2Department of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, South Australia, Australia, 3Department of Ophthalmology, Flinders University,
Bedford Park, South Australia, Australia
Abstract
It has recently been shown that there are highly significant associations for common single nucleotide polymorphisms
(SNPs) near the CDKN2B-AS1 gene region at the 9p21 locus with primary open angle glaucoma (POAG), a leading cause of
irreversible blindness. This gene region houses the CDKN2B/p15INK4B, CDKN2A/p16
INK4A and p14ARF (rat equivalent, p19ARF)
tumour suppressor genes and is adjacent to the S-methyl-59-thioadenosine phosphorylase (MTAP) gene. In order to
understand the ocular function of these genes and, therefore, how they may be involved in the pathogenesis of POAG, we
studied the distribution patterns of each of their products within human and rat ocular tissues. MTAPmRNA was detected in
the rat retina and optic nerve and its protein product was localised to the corneal epithelium, trabecular meshwork and
retinal glial cells in both human and rat eyes. There was a very low level of p16INK4A mRNA present within the rat retina and
slightly more in the optic nerve, although no protein product could be detected in either rat or human eyes with any of the
antibodies tested. P19ARF mRNA was likewise only present at very low levels in rat retina and slightly higher levels in the
optic nerve. However, no unambiguous evidence was found to indicate expression of specific P19ARF/p14ARF proteins in
either rat or human eyes, respectively. In contrast, p15INK4B mRNA was detected in much higher amounts in both retina and
optic nerve compared with the other genes under analysis. Moreover, p15INK4B protein was clearly localised to the retinal
inner nuclear and ganglion cell layers and the corneal epithelium and trabecular meshwork in rat and human eyes. The
presented data provide the basis for future studies that can explore the roles that these gene products may play in the
pathogenesis of glaucoma and other models of optic nerve damage.
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Introduction
Glaucoma is a leading cause of irreversible blindness and
manifests as an age-related, progressive optic neuropathy with a
poorly understood pathogenesis and limited treatment options [1].
It affects approximately 2.5% of the general population over 40
years of age, with the prevalence increasing exponentially
thereafter [2,3]. The most common form of glaucoma is primary
open-angle glaucoma (POAG), which has a poorly understood
cause and pathogenesis but which makes up approximately 74% of
all cases [3]. This particular form of glaucoma is usually treated by
lowering intraocular pressure (IOP). Although such a treatment
regimen can delay progression of the disease in many cases,
patients often present only after irreversible retinal damage has
occurred. Therefore, further research is essential to address the
underlying causes of POAG.
In recent years, researchers have attempted to elucidate
pathological mechanisms involved in the etiology of POAG by
identifying familial links that may indicate a genetic basis for this
disease. The first gene to be identified as such was MYOC which
encodes the myocilin protein in trabecular meshwork (TM) cells
[4,5]. Indeed, MYOC mutations are now known to underlie 3–5%
of POAG cases. Other genes identified in a similar manner to play
potential roles in glaucoma pathogenesis are the OPTN [6], the
NTF4 [7] and the WDR36 [4] genes.
A related analytical tool employed to aid elucidation of the
pathogenesis of POAG has been the genome-wide association
study (GWAS). This method determines the prevalence of single
nucleotide polymorphisms (SNPs) at distinct genetic loci which are
significantly associated with a particular disease: in this case,
POAG. The first SNP location reproducibly identified using a
GWAS approach was the CAV1/CAV2 locus on chromosome
7q34, which encodes the caveolin 1 and caveolin 2 proteins [5,6].
More recent studies identified significant genome-wide association
with POAG at the rs4656461 SNP near the TMCO1 gene
(encoding transmembrane and coiled-coil domain-containing
protein 1; TMCO1) on chromosome 1q24 [7,8,9]. Subsequent
analysis of TMCO1 expression within the human eye showed that
although having an unknown function, this protein localised to
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nuclear inclusions (nucleoli) in most tissue regions, including both
the retina and trabecular meshwork, implying a role in cellular
control [10].
The most significant region to be identified, by independent
research groups, as having an association with POAG in different
population samples is the CDKN2B-AS1 region on chromosome
9p21 [7,8,11,12,13,14,15,16,17,18,19,20]. The significance of this
finding derives from the fact that SNPs which affect genetic
expression in the region of CDKN2B-AS1 are known to be
associated with a number of diseases such as coronary heart
disease [21,22,23], types 1 and 2 diabetes [21,24,25], atheroscle-
rosis [26] and different cancers (see reviews by Pasmant et al., 2011
and Cunnington et al., 2010 [24,25]). CDKN2B-AS1 or ANRIL
(anti-sense non-coding RNA at the INK4 locus) encodes an
extended non-coding RNA spanning 19 exons which resides in the
CDKN2B/p15INK4B-CDKN2A/p16INK4A-p14ARF tumor sup-
pressor gene cluster [27] (see figure 1). This RNA gene is also
adjacent to the MTAP gene, which encodes the protein S-methyl-
59-thioadenosine phosphorylase (MTAP) [28]. The proteins
p15INK4B and p16INK4A are involved in cellular proliferation
and senescence by inhibiting cyclin-D binding at cell cycle-
regulating cyclin-dependent kinases [29]. Human p14ARF (rat
homologue is p19ARF) is transcribed from an alternate reading
frame of the p16INK4A locus in response to sustained mitogenic
stimulation, and is involved with nucleolar regulation of ribosome
biosynthesis, initiation of p53-dependent cell cycle arrest and
apoptosis [36,37]. MTAP is involved with polyamine, methionine
and adenine metabolism [28]. Thus, SNPs causing altered
expression of any of the genes derived from this region of the 9p
chromosome may have serious pathological consequences.
Since it is known that SNPs associated with the CDKN2B-AS1
gene region effectively comprise a major ‘‘hotspot’’ that relates to
many diseases [24,25], then the finding that this region is strongly
and reproducibly associated with POAG is extremely significant.
The present study therefore sought to investigate the ocular
expression and localisation patterns of products from the
CDKN2B-AS1 gene region. Detailed information on the previously
unstudied ocular expression profiles of the gene products encoded
by these loci, is likely to be of great importance in determining
their role in glaucoma pathogenesis.
Materials and Methods
Tissue Collection
Adult Sprague-Dawley (SD) rats (8–10 weeks old) were obtained
from The University of Adelaide and were housed according to
the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes, 2004, and the Association for Research in
Vision and Ophthalmology (ARVO) Statement for the Use of
Animals in Ophthalmic and Vision Research. The work was
approved by the South Australia (SA) Pathology/Central North-
ern Health (CNH) Animal Ethics Committee. No actual exper-
imental procedures were carried out on animals: when tissue was
required, all tissues were procured by rapid killing of animals
under terminal anaesthesia by trans-cardiac perfusion with 0.9%
(w/v) NaCl solution to achieve exsanguination. In some cases, rat
liver and brain cortex samples were also prepared (for Western
immunoblot or reverse-transcription polymerisation chain reac-
tion; RT-PCR). For some optic nerve analysis, pigmented inbred
Dark Agouti (DA) rats (8–10 weeks old) were also analysed:
samples from these animals were prepared in the same way as for
the standard SD rats. For each antibody tested, and each
analytical method used, at least 6 animals were assessed. Human
ocular tissue for analysis was obtained from the Eye-Bank of South
Australia, Flinders Medical Centre (Adelaide, Australia) following
the guidelines of the Southern Adelaide Clinical Human Research
Ethics Committee; all had been screened to make sure there was
no underlying ocular disease and all were from Caucasian donors
between the ages of 50 and 65. Tissue sections of malignant
pleural mesothelioma and cervical adenocarcinoma, which served
as positive controls in the present study, were sourced from
positive control blocks provided by the Surgical Diagnostic facility
of SA Pathology (Adelaide, Australia).
Antibodies
A review of the relevant literature revealed that each of the
protein products to be analysed (MTAP, p14ARF [human tissue],
p19ARF [rat tissue], p16INK4A, p15INK4B) have had their expression
in various tissues determined by the use of a number of antibodies.
It was therefore decided in the interests of accuracy and
consistency to use a selection of the most frequently used
antibodies for each protein under analysis, in order to determine
the most reproducible expression/localisation data. Antibody data
is summarised in Table 1.
Other un-related antibodies (eg. b-actin, Ret-P1 for rhodopsin,
a-tubulin, FGF-2, vimentin, CD45, glutamine synthetase) were
used as described previously [30], with appropriate dilutions
recorded where employed.
Recombinant Proteins as Positive Controls
To test the specificity for each antibody under investigation,
recombinant proteins for each of the species under test were
obtained. These were to enable positive reactivity testing and pre-
Figure 1. Genomic organisation of the human 9p21 gene cluster. Organisation of the CDKN2A/ARF, CDKN2B and CDKN2B-AS1 genes at the
9p21 locus and the neighbouring gene, MTAP. The boxes represent exons, numbers in boxes correspond to exon numbers, lines between boxes
represent introns/intergenic regions, V-lines represent exon-splicing, arrows represent encoded transcript/protein and double-slash indicates large
intergenic region. The two gene products, CDKN2A and ARF, encoded by the CDKN2A/ARF gene are respectively represented in red and light red. The
SNP most significantly associated with open-angle glaucoma in the CDKN2B-AS1 gene is represented by an orange diamond. Note: the figure is not
drawn to scale.
doi:10.1371/journal.pone.0075067.g001
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adsorption neutralisation for each relevant antibody. A human-
specific protein/peptide for p14ARF was unable to be obtained,
although a rodent-specific version (p19) was procured. p19ARF
peptide was from Abcam (Cambridge, UK; #ab2659; 5 mg/ml)
and p16INK4A, p15INK4B and MTAP proteins were obtained from
Abnova (Walnut, CA, USA). The latter three products were
obtained as GST-fusion products; hence these peptides had
molecular masses that were 26 kD larger than reported values in
each case (due to the additional mass of GST). Details: p15INK4B,
human sequence with full length ORF (residues 1–138),
#H00001030-P01, 0.04 mg/ml; p16INK4A, human sequence with
full length ORF (residues 1–105), #H00001029-P01, 0.25 mg/ml;
MTAP, human sequence with full length ORF (residues 1–283),
#H00004507-P01, 0.09 mg/ml.
Tissue Processing and Immunohistochemistry
Whole eyes plus attached optic nerves that were subsequently
used for immunohistochemistry were immersion-fixed in either
10% (w/v) neutral buffered formalin for 24–72 h until processing,
or in Davidson’s solution (2 parts 37% formaldehyde, 3 parts
100% ethanol, 1 part glacial acetic acid and 3 parts water) for 24 h
followed by 70% ethanol until processing. Davidson’s solution is
the preferred fixative for whole eyes as it provides optimal tissue
preservation without artefactual retinal detachment. Eyes were
subsequently hand-processed according to the following schedule:
70% ethanol (30 min), 36100% ethanol (30 min), 26xylene
(30 min), 50% xylene/50% wax (30 min) at 62uC, 26wax
(30 min) at 62uC. Globes were embedded in a sagital orientation
and 4 mm sections were cut using a rotary microtome.
Immunohistochemistry of transverse ocular sections was
performed as previously described [30,31]. Briefly, tissue sections
were deparaffinised and endogenous peroxidase activity was
blocked with H2O2. Antigen retrieval was performed by micro-
waving sections in 1 mM EDTA (pH 8.0) and non-specific
labelling blocked with PBS containing 3% normal horse serum
(PBS-HS). Sections were incubated overnight at room temperature
in primary antibody (in PBS-HS), followed by consecutive
incubations with biotinylated secondary antibody (Vector, Burlin-
game, CA) and streptavidin-peroxidase conjugate (Pierce, Rock-
ford, IL). Color development was achieved using NovaRed
substrate kit (Vector, Burlingame, CA) for 3 min. Sections were
counterstained with hematoxylin, dehydrated, cleared in histolene
and mounted in DPX. In order to evaluate specificity of antibody
labelling, adjacent sections were incubated with the appropriate
isotype control for monoclonal antibodies, or normal rabbit/goat
serum for polyclonal rabbit/goat antibodies. In addition, Western
blotting was performed for the majority of the antibodies used.
For antibody-antigen neutralisation studies, antibodies were
pre-adsorbed with or without a ten-fold excess of the appropriate
recombinant protein in PBS-HS for three hours on a rotary shaker
at room temperature before being applied to sections in a standard
manner.
Western Immunoblotting
Dissected tissue was sonicated in homogenisation buffer
(20 mM Tris-HCl, pH 7.4, 25uC; with 2 mM EDTA, 0.5 mM
EGTA, 1 mM dithiothreitol, 50 mg/ml leupeptin, 50 mg/ml
pepstatin A, 50 mg/ml aprotinin and 0.1 mM phenylmethylsul-
phonyl fluoride). An equal volume of sample buffer (62.5 mM
Tris-HCl, pH 7.4, containing 4% SDS, 10% glycerol, 10% b-
mercaptoethanol and 0.002% bromophenol blue) was subsequent-
ly added and samples were boiled for 5 minutes. In order to ensure
even running of samples on gels, protein concentrations for each
tissue extract were equalized according to the method of Bradford
[32].
Electrophoresis was performed using a Mini-PROTEANH
TGXTM precast gel system (Bio-Rad Laboratories Pty Ltd,
Gladesville, New South Wales, Australia). Denaturing 12% (w/v)
polyacrylamide gels were employed for protein separation, as
described previously [33]. Separated proteins were transferred to
Table 1. Antibodies used for detection of 9p21-related gene products.
Protein Species Antibody Clone/Cat. No. Species Concentration Dilution
MTAP Proteintech 1475-1-AP Rabbit 133 mg/ml 1:800, 1:2000W
Santa Cruz sc-100782 Mouse 100 mg/ml 1:100, 1:1000W
CST #4158 Rabbit 13.5 mg/ml 1:100, 1:1000W
p14ARF Santa Cruz sc-8340 Rabbit 200 mg/ml 1:1000, 1:1000W
Sigma DCS-240 Mouse 2 mg/ml 1:1000, 1:2000W
p19ARF Upstate 07-543 Rabbit 100 mg/ml 1:100, 1:1000W
Santa Cruz G-19 Goat 200 mg/ml 1:100, 1:2000W
p15INK4B Santa Cruz K-18 Rabbit 200 mg/ml 1:500, 1:500W
Neomarkers {15P06 Mouse 200 mg/ml 1:500, 1:1000W
CST #4822 Rabbit 34 mg/ml 1:1000, 1:1000W
Abcam Ab53034 Rabbit 1 mg/ml 1:1000, 1:1000W
p16INK4A Santa Cruz `sc-1661 Mouse n/a n/a
Proteintech 10883-1-AP Rabbit 146 mg/ml 1:500, 1:1000W
Sigma 4C11 Mouse 1 mg/ml 1:500, 1:1000W
Abnova 2D9A12 Mouse 1 mg/ml 1:2000, 1:1000W
Wdilution used for Western blotting; CST, Cell Signalling Technology;
{discontinued product;
`sc-1661 is exclusively under licence to CINtecH within Australia as the primary antibody component of an immunohistochemistry assay for detection of p16INK4A in
cervical tissue sections.
doi:10.1371/journal.pone.0075067.t001
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polyvinylidine fluoride membranes (PVDF; Bio-Rad Laboratories
Pty Ltd) for labelling. Membranes were incubated with appropri-
ate primary antibody overnight, and actual labelling of immuno-
blots carried out using a two-step detection procedure: first,
appropriate biotinylated secondary antibodies were applied
(Vector Laboratories; 1:500; 30 minutes) and subsequently
streptavidin-peroxidase conjugates (Pierce, Rockford, Il, USA).
Blocking of membranes was carried out in a solution of tris-
buffered saline (TBS) containing 0.1% (v/v) Tween-20 and 5%
(w/v) non-fat dried skimmed milk (TBS-TM). Positive antibody
labelling was detected as described previously [39] and quantifi-
cation of detected proteins was achieved, where appropriate, using
the program, Adobe PhotoShop CS2. Detection of b-actin was
assessed where suitable as a positive gel-loading control.
For Western immunoblot testing of specificity of each
antibody to recognise the appropriate antigen, recombinant
proteins were resolved on 12% SDS-PAGE gels after loading at
either 100 ng or 10 ng per lane before being detected as
described above.
Real-time PCR
Real time PCR studies were carried out essentially as
described previously [30,31]. In brief, the required tissues were
dissected, total RNA was isolated and first strand cDNA was
synthesised from DNase-treated RNA samples. Real-time PCR
reactions were carried out in 96-well optical reaction plates
using the cDNA equivalent of 20 ng total RNA for each sample
in a total volume of 25 ml containing 16SYBR Green PCR
master mix (BioRad), forward and reverse primers. Thermal
cycling conditions were 95uC for 3 min and 40 cycles of
amplification comprising 95uC for 12 s, appropriate annealing
temperature for 30 s and 72uC for 30 s. Primers employed for
the study are outlined in Table 2. To allow a comparison to be
made between the levels of expression of test mRNAs in the
different tissues, results were semi-quantified using the Relative
Expression Software Tool (REST). Threshold cycles were
calculated using IQ5 icycler Software (Bio-Rad), all values were
normalised using the endogenous reference gene, cyclophilin,
and results expressed as mean 6 SEM.
RGC-5 Cell-Line
This murine cell-line [34] comprises retina-derived cells which
can be differentiated into neurons [35]. They were cultivated
exactly as described previously [36]. Their use in the present study
was to provide a positive control preparation for identification of
P19ARF.
Immunocytochemical Analysis of Cultures
Cells on coverslips were fixed with neutral-buffered formalin
containing 1% methanol for 15 minutes and then washed in
phosphate buffered saline (PBS; 137 mM NaCl, 5.4 mM KCl,
1.28 mM NaH2PO4, 7 mM Na2HPO4; pH 7.4). Cells were
permeabilised with PBS containing 0.1% (v/v) Triton X-100
(PBS-T), followed by further washing in PBS and then blocking in
PBS-HS. Test antisera (see Table 1), diluted in PBS-HS, were
applied overnight at room temperature and labelling completed
with consecutive incubations in appropriate biotinylated second-
ary antibodies (Vector Laboratories, Abacus ALS, Brisbane,
Australia; 1:250 in PBS-HS; 30 minutes) and streptavidin-
AlexaFluor 488 or streptavidin-AlexaFluor 594 (Molecular
Probes, Invitrogen, Mulgrave, Victoria, Australia; 1:500 in PBS-
HS; 1 hour). Cells on coverslips were mounted using anti-fade
mounting medium (DAKO, Botany, New South Wales, Australia)
and examined under a confocal fluorescence microscope.
Results
MTAP
RT-PCR. Table 3 shows the expression level of MTAP
mRNA, relative to the housekeeping gene cyclophilin, in four rat
tissues (brain cortex, liver, optic nerve and retina) using two
distinct sets of primers to ensure reproducibility. The first point to
note is that there was a good agreement between the two primer
sets. Regarding abundance, there was a broadly similar level of
MTAP mRNA across the different tissues. The MTAP transcript
is present at approximately 0.3% and 1% of the level of
glyceraldehyde-3-phosphate dehydrogenase and cyclophilin, re-
spectively, in retina and optic nerve, with somewhat higher and
lower levels present in the liver and brain samples, respectively.
Table 2. Primer Sequences for mRNAs Amplified by Real-Time RT-PCR.
mRNA Primer sequences
Product
size (bp)
Mg2+
concn
Annealing
temperature
Accession
number
cyclophilin 59-GTGTTCTTCGACATCACGGCT-39 82 3 mM 63uC NM_017101
59-CTGTCTTTGGAACTTTGTCTGCA-39
MTAP (set 1) 59-TGGAATAATTGGTGGAACAGGC-39 513 3.5 mM 62uC NM_001047867
59-TGGCACACTCCTCTGGCAC-39
MTAP (set 2) 59-AGTGTCAGTGGATGGGGTTT-39 122 3.5 mM 62uC NM_001047867
59-TTAGGTTACGGAGCGTTTCTG-39
p15INK4B 59-AGATCCCAACGCCGTCAAC-39 184 3.5 mM 61uC NM_130812
59-CAGCACCATTAGCGTGTCCAG-39
p16INK4A/p19ARF 59-CGTGCGGTATTTGCGGTATCT-39 171 3.5 mM 61uC NM_031550
59-GCCAGAAGTGAAGCCAAGGA-39
p16INK4A 59-TGCAGATAGACTAGCCAGGGC-39 185 3.5 mM 59uC NM_031550
59-CTCGCAGTTCGAATCTGCAC-39
p19ARF 59-GGTCGCAGGTTCGTGGTC-39 412 3.5 mM 61uC AY679727
59-GTCGTGATGTCCCCGCTCT-39
doi:10.1371/journal.pone.0075067.t002
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Antibody validation. To investigate ocular expression of
MTAP protein, three distinct commercially available antibodies
(CST, Santa-Cruz, Proteintech) were obtained. Initially, each
antibody was tested for reactivity against recombinant human
MTAP (rMTAP), which, when conjugated to GST, has a
predicted molecular mass of 57 kD. All three antibodies were
able to detect 100 ng rMTAP (figure 2A); the Proteintech and
Santa-Cruz antibodies also detected 10 ng rMTAP (Fig. S1A).
When incubated with rat tissue extracts, all three antibodies were
able to distinguish proteins at the predicted molecular mass
(31 kD) in liver and retina, but only the Proteintech and Santa-
Cruz preparations detected a signal in the optic nerve (Fig. 2,
S1B).
Previous work has used immunohistochemistry to reliably detect
MTAP expression in formalin-fixed, paraffin-embedded malignant
pleural mesothelioma [37]. As a consequence, such tissue served as
a positive control in the present study, both in terms of analyzing
the sensitivity of the various primary antibodies used and in
verifying the effectiveness of our immunohistochemistry method-
ology. The MTAP antibody from Proteintech correctly identified
inflammatory cells and fibroblasts with a good signal-to back-
ground ratio (Fig. 2D–G). This finding, coupled with the positive
results obtained from the Western blotting experiments, attested to
its reliability in detecting MTAP. In contrast, the antibodies from
CST and Santa-Cruz yielded weaker patterns of immunolabelling
than that obtained with the Proteintech antibody (Fig. S2), even at
low antibody dilutions. This result was replicated when the
antibodies were tested on ocular sections, hence only data
obtained using the Proteintech antibody are shown hereafter.
Ocular expression of MTAP. In human eye sections,
MTAP was associated with cells in the corneal epithelium,
trabecular meshwork and retina (Fig. 3A–C). Further investigation
of the localisation within the retina, which was achieved by
double-labelling immunofluorescence with glutamine synthetase,
revealed MTAP immunoreactivity to be principally associated
with astrocytes and Mu¨ller cells (Fig. 3D–F). An association with
neuronal components cannot be ruled out, however. MTAP
displayed a broadly similar pattern of immunolabelling in rat
ocular sections to that observed in humans (Fig. 3-L). Of note,
however, in the retina MTAP appeared to be restricted to
astrocytes. Unlike the human eye, no labelling of Mu¨ller cell somas
or processes was apparent.
Analysis of retina and optic nerve samples from three rats
revealed MTAP expression in all samples (Fig. 2C). Densitometry
indicated that although there was a tendency for there to be a
higher expressed level of the MTAP protein in the retina versus
the optic nerve, this was not statistically significant (Fig. 2C).
P16INK4A (CDKN2A)
RT-PCR. P16INK4A and p19ARF are both products of the rat
CDKN2A gene, each having a unique first exon, but sharing exons
2 and 3. In preliminary results, contained within our previous
study [7], we made use of primers that amplified a cDNA region
common to both mRNAs. Herein, we have again used these
primers for comparative purposes, but also primers specific to each
transcript. Table 4 shows the expression level of p16INK4A mRNA,
relative to the housekeeping gene cyclophilin, in rat brain cortex,
liver, optic nerve and retina. The common primers detected a very
low level of expression of p16INK4A/p19ARF in the brain, retina
and liver, but a greater amount within optic nerve samples. Using
the p16INK4A-specific primers, a very low level of expression was
measured in all four tissues, which, in the retina and optic nerve,
approximated to 0.001% and 0.006%, respectively, of the level of
cyclophilin.
Antibody validation. For dissemination of expression levels
of the p16INK4A protein in ocular tissues, four antibodies (Santa-
Cruz, Proteintech, Sigma and Abnova) were investigated (Figs. S3,
S4; see also Fig. 4). Full length GST-tagged recombinant p16INK4A
protein was initially used as a positive control to determine
antibody reactivity (Fig. S3A). The Proteintech, Sigma and Santa-
Cruz (see also Fig. 4A) antibodies detected the recombinant
protein at the correct molecular mass; the Abnova antibody did
not recognise any protein signal. None of the antibodies reacted
against recombinant p15INK4B protein (data not shown). Subse-
quent analysis of the antibodies in rat brain, liver, optic nerve and
retina determined that none of the four tissues under investigation
expressed measureable amounts of p16INK4A protein (Fig. S3B; see
also Fig. 4B). Overexpression of p16INK4A protein is consistently
encountered in cervical dysplasias, neoplasias or carcinomas of
squamous and glandular cell/tissue types that are associated with
high-risk human papillomavirus infection. Indeed, immunohisto-
chemistry for p16INK4A is currently the subject of much attention
regarding its suitability as a biomarker for cervical cancer
screening [38,39]. As such, formalin-fixed, paraffin-embedded
tissue sections from abnormal cervical tissue represented the ideal
positive control for p16INK4A immunohistochemistry in the
current study (Fig. S4). The antibodies from Santa-Cruz (see also
Fig. 4D, E), Proteintech, and, to a somewhat lesser extent, Sigma
identified p16INK4A-overexpressing glandular and epithelial cells
with good signal-to background ratios. The p16INK4A antibody
from Abnova less reliably demarcated abnormal tissue and elicited
Table 3. Expression of MTAP mRNA in rat tissues.
retina optic nerve brain liver
cyclophilin CT 17.660.1 19.560.2 18.260.1 19.560.2
MTAP CT 24.660.1 27.060.2 26.660.1 26.560.3
(primer set 1) 1DCT 7.060.1 7.060.1 8.460.1 7.160.0
2mRNA level 0.01060.001 0.01060.001 0.00460.000 0.00960.002
MTAP CT 24.660.1 26.760.1 26.260.1 25.860.3
(primer set 2) 1DCT 6.960.1 6.760.1 8.060.0 6.360.0
2mRNA level 0.01060.001 0.01260.002 0.00560.000 0.01560.003
CT, cycle threshold;
1DCT, target CT - cyclophilin CT;
2target mRNA level expressed relative to cyclophilin.
doi:10.1371/journal.pone.0075067.t003
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Figure 2. Evaluation of MTAP expression in ocular tissues. (A) Evaluation of the MTAP antibody by Western immunoblotting using GST-
tagged, full length, recombinant, human MTAP protein (rMTAP). Molecular weight markers were used to determine size of detected gel products (A;
lane M). Lane 1, 100 ng rMTAP; Lane 2, 10 ng rMTAP; Lane 3, 1 ng rMTAP; Lane 4, 100 pg rMTAP. A single band of the expected molecular weight
9p21 Gene Region Products in the Mammalian Eye
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robust nuclear labelling of cells in surrounding tissue. The
combined data raise serious questions about the specificity of the
Abnova antibody, but indicate that data obtained from the other
antibodies are valid.
Ocular expression of p16INK4A. In human eye sections,
incubated identically to and simultaneously with cervical tissue
sections, no specific p16INK4A immunolabelling was observed in
the cornea, drainage angle, retina or optic nerve (Fig. 5A, B, C; see
also Fig. S5); note the presence of pigment and not positive
immunolabelling in the TM/Schlemm’s Canal images (Fig. 5B).
More concentrated dilutions simply resulted in generic, non-
specific staining (data not shown). Similarly, in rat ocular sections,
no unambiguous evidence was found for p16INK4A protein
expression in the cornea, retina or optic nerve (Fig. 5D, E, F;
see also Fig. S6). In agreement with these findings, Western
immunoblotting analysis of retina and optic nerve from three rats
revealed no expression of p16INK4A in any sample (Fig. 4C; see
also Fig. S3C).
P14ARF
Antibody validation. P14ARF, the human homologue of
p19ARF, has been shown to be localized mainly in the cellular
nucleolus; it is also present in the nucleoplasm of cells expressing
the protein [40]. Characteristically, induction of p14ARF occurs in
response to inappropriate hyperproliferative signals, such as in
cancerous tissues. Alongside p16INK4A, expression of p14ARF has
consistently been detected in abnormal cervical tissue [40,41];
thus, we again used formalin-fixed, paraffin-embedded tissue
sections from cervical lesions as a positive control for p14ARF
immunohistochemistry. Both antibodies tested (Sigma and CST)
identified p14ARF expression in nuclear inclusions within epithelial
cells in abnomal cervical tissue, with the antibody from Sigma
(Fig. 6A) displaying a better signal-to background ratio than the
antibody from CST (Fig. S7A).
Ocular expression of p14ARF. In human eye sections,
incubated identically to and simultaneously with cervical tissue
sections, neither antibody revealed any specific, nuclear p14ARF
immunolabelling in the cornea, drainage angle, retina or optic
nerve (Fig. 6B, C, D, E, F; Fig. S7).
P19ARF
RT-PCR. Table 4 shows the expression level of p19ARF
mRNA, relative to the housekeeping gene cyclophilin, in rat brain,
liver, optic nerve and retina. As noted above, the common primers
detected a very low level of expression of p16INK4A/p19ARF in the
brain, retina and liver, but a greater amount within optic nerve
samples. Using the p19ARF-specific primers, it was confirmed that
the levels of transcript in the brain, liver and retina were indeed
low (approximately 0.003–0.007% of the level of cyclophilin), and,
that the greater amount in the optic nerve (approximately 0.2% of
the level of cyclophilin) represented p19ARF rather than p16INK4A.
Antibody validation and ocular expression. Expression of
p19ARF protein in rat ocular tissues was examined using two
distinct, commercially-available antibodies (Upstate, Santa-Cruz).
Initially, to visualise positive immunolabelling for P19ARF,
transformed, retina-derived, undifferentiated, rodent RGC-5 cells
were grown to confluence and stained with both antibodies. The
rationale for this test is that previous work has demonstrated
p19ARF localization in the nucleolus of immortalised cells [42].
The Santa-Cruz antibody appeared to label only some cytoplas-
mic granules (Fig. 7A, B, C), but the Upstate antibody clearly
labelled nuclear inclusions (Fig. 7D, E, F). Since the immunocy-
tochemical labelling in RGC-5 cells with the Upstate antibody
resembled that reported previously for other immortalised cells
[42], we believe this to be specific labelling and therefore the most
applicable antibody for future studies.
To further verify the specificity of the Upstate and Santa-Cruz
antibodies, both preparations were tested against recombinant rat
p19ARF by Western blotting. The Upstate antibody clearly
detected 100 ng and 10 ng recombinant p19ARF, but the Santa-
Cruz antibody was unable to distinguish any signal (Fig. 8A).
When analyzing rat tissue samples, however, the Upstate antibody
failed to detect any proteins at the correct molecular mass (19 kD).
Moreover, in brain cortex and optic nerve samples a protein with
a mass of 48 kD was detected, and in liver and retina samples a
protein with the mass of 35 kD was weakly distinguished (Fig. 8B).
This was confirmed when 3 independent retina and optic nerve
samples were analysed (Fig. 8C). From these results, it appears
likely that the Upstate antibody cross-reacts with other proteins.
Surprisingly, since it did not cross-react with the recombinant rat
p19ARF, the Santa-Cruz antibody detected a 19 kD protein in
optic nerve but not retina, brain cortex or liver samples (Figs. 8B,
C).
Immunohistochemistry. In rat ocular sections, no evidence
was found for nuclear p19ARF protein expression in the anterior
segment (data not shown), retina (Fig. 8D) or optic nerve (Fig. 8D)
when using the Upstate antibody. Interestingly, sections through
the rat optic nerve head demonstrated a cross-reaction of the
antibody with the myelinated portion of the optic nerve (Fig. 8D).
This quite likely accounts for the non-specific band at 48kD
observed in Western blots. As regards the Santa-Cruz antibody, no
nuclear p19ARF protein expression was observed in the anterior
segment, retina or optic nerve (data not shown).
The overall results for p19ARF suggest that the protein is not
present at detectable levels in rat ocular tissues; however, the
profile of neither antibody is totally convincing and some doubt
remains.
P15INK4B (CDKN2B)
RT-PCR. Table 5 shows the expression level of p15INK4B
mRNA, relative to the housekeeping gene cyclophilin, in rat brain,
liver, optic nerve and retina. The p15INK4B transcript is present in
considerably higher amounts in the optic nerve than in the retina
(approximately 1.8% and 0.02% of the level of cyclophilin,
respectively). Of interest is the fact that in both tissues expression
was markedly higher than for p16INK4A. The levels of p15INK4B
mRNA in the brain and liver were broadly similar to that
measured in the retinal samples.
Antibody validation. To determine expression of p15INK4B
in rat ocular tissues, four distinct, commercially available
(including GST-tag) is apparent; results plotted on bar graph to show quantitative distribution. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve
(lane 3) and retina (lane 4) samples probed for MTAP. A protein is detected at the correct molecular mass for MTAP in the liver, optic nerve and retinal
samples. Labelling for b-actin (housekeeping gene) and a-tubulin (neuronal tissue marker) are also shown; results plotted on bar graph to show
quantitative distribution. (C) Evaluation of MTAP expression in retina (lanes 1–3) and optic nerve (lanes 4–6) samples obtained from three different
rats. MTAP protein is detectable in all samples; results plotted on bar graph to show quantitative distribution. (D–G) Evaluation of MTAP antibodies in
malignant pleural mesothelioma. In formalin-fixed, paraffin-embedded tissue sections, many inflammatory cells, as identified by immunoreactivity for
CD45 (leukocyte common antigen; D), display positive labelling for MTAP using the Proteintech antibody (PT Ab; E). Some fibroblastic cells, negative
for CD45 (F), also display positive labelling for MTAP using the PT antibody (G, arrow). Scale bar = 30 mm.
doi:10.1371/journal.pone.0075067.g002
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antibodies (CST; Neomarkers; Abcam; Santa-Cruz) were em-
ployed. Initially, each antibody was tested against recombinant rat
p15INK4B by Western blotting. Next, each antibody was tested
against a variety of rat tissues by Western blotting. For the
purposes of immunohistochemistry, antibodies were validated
using formalin-fixed, paraffin-embedded tissue sections from
abnormal cervical tissue and normal skin, since p15INK4B positive
immunolabelling has previously been detected in cervical intraep-
Figure 3. Representative images of MTAP immunolabelling in human (A–F) and rat (G–L) ocular tissues. In formalin-fixed, paraffin-
embedded human eyes, positive labelling for MTAP is discernible in cells located in the corneal epithelium (A) and trabecular meshwork/Schlemm’s
canal (B). In the retina, MTAP labelling is associated with astrocytes (arrow) and Mu¨ller cell somas (inset) and processes (C). Verification of MTAP
expression by Mu¨ller cells was obtained by double-labelling immunofluorescence of MTAP (red) with the Mu¨ller cell marker glutamine synthetase
(Glut Syn; green; D–F). In formalin-fixed, paraffin-embedded rat eyes positive labelling for MTAP is similarly detectable in corneal epithelial cells (G).
Interestingly, in eyes fixed in Davidson’s solution, which affords superior morphological preservation, MTAP expression is strongly detected within the
membranes of corneal epithelial cells (H). In the retina (I), ONH (J) and ON (K), MTAP labelling is principally localised to astrocytes. The pattern of
immunoreactivity displays marked similarity to GFAP, as illustrated in (L). Scale bar: A, D–L = 15 mm; B, C = 30 mm. TM, trabecular meshwork; SC,
Schlemm’s canal; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; ONH, optic nerve head.
doi:10.1371/journal.pone.0075067.g003
9p21 Gene Region Products in the Mammalian Eye
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e75067
ithelial neoplastic lesions [43] and in cutaneous squamous cells
[44].
The p15INK4B antibody from CST was able to detect the correct
mass protein (GST-p15INK4B; 41 kD) when present at 100 pg-
100 ng (Fig. 9A), but importantly did not cross-react with
recombinant GST-p16INK4A (Fig. 9B). When tested against a
variety of rat tissues by Western blotting, the CST antibody
correctly recognised 15 kD products: in particular, positive
reactivity was detected in liver (as defined previously [45]), retina
and optic nerve (Fig. 9C). The specificity of the CST antibody was
confirmed in additional retina and optic nerve samples (Fig. 9D),
where no significant differences were found in expression levels. In
tissue sections from abnormal cervical tissue (Fig. 10A) and normal
skin (Fig. 10B), the CST antibody yielded patterns of immuno-
labelling in agreement with those previously described [43,44].
These results attest to the validity of the CST antibody for
recognition of the p15INK4B protein. In contrast, the p15INK4B
antibodies from Neomarkers, Abcam and Santa-Cruz produced
unsatisfactory results (see Figs. S8, S9).
Ocular expression of p15INK4B. In human eye sections,
p15INK4B immunolabelling, as identified by use of the CST
antibody, was associated with the nuclei of cells located in the
corneal epithelium, trabecular meshwork and inner retina
(Fig. 10C, D, E, F). In rat eye sections, p15INK4B immunolabelling
Table 4. Expression of P16INK4A/P19ARF mRNA in rat tissues.
retina optic nerve brain liver
cyclophilin CT 17.660.1 19.560.2 18.260.1 19.560.2
P16INK4A/ CT 32.160.4 27.160.3 33.860.2 32.460.4
P19ARF 1DCT 14.560.4 7.660.2 15.660.1 12.960.2
2mRNA level 8610256261025 0.00760.001 3610256361026 26102460.002
P16INK4A CT 34.760.1 35.460.3 36.860.4 37.360.0
1DCT 17.260.1 15.060.3 18.660.3 17.860.4
2mRNA level 1610256161026 6610256261025 4610266161026 1610256161026
P19ARF CT 32.660.5 28.960.2 33.860.1 35.060.4
1DCT 15.060.5 9.460.1 15.660.0 15.560.4
2mRNA level 7610256361025 0.0026361024 3610256161026 3610256161026
CT, cycle threshold;
1DCT, target CT - cyclophilin CT;
2target mRNA level expressed relative to cyclophilin.
doi:10.1371/journal.pone.0075067.t004
Figure 4. Validation of the p16INK4A antibody from Santa-Cruz (sc-1661). (A) Evaluation of the specificity of the p16INK4A antibody, sc-1661,
by Western blotting, using GST-tagged, full length, recombinant, human p16INK4A protein (rp16INK4A). Molecular weight markers were used to
determine size of detected gel products (A; lane M). Lane 1, 100 ng of rp16INK4A; Lane 2, 10 ng rp16INK4A. A single band of the expected molecular
weight (including GST-tag) is apparent. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for p16INK4A
protein, using sc-1661. None of the four tissues under investigation unambiguously express p16INK4A protein. Labelling for b-actin (house-keeping
gene product) is also shown. (C) The antibody was further tested against retina (lanes 1–3) and optic nerve (lanes 4–6) samples obtained from three
different rats. The presence of p16INK4A protein is not detectable in any sample. (D, E) In formalin-fixed, paraffin-embedded tissue sections of cervical
adenocarcinoma, incubation with sc-1661, identifies so-called ‘block’ or ‘diffuse’ immunolabelling of ductal (D) and epithelial (E) tissue with a high
signal-to-background, as compared to adjacent tissue (arrow). Scale bar = 30 mm.
doi:10.1371/journal.pone.0075067.g004
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was associated with nuclei in the ganglion cell and inner nuclear
layers, but not in the outer nuclear layer (Fig. 11A). Preadsorption
with recombinant p15INK4B protein reduced the intensity of
labelling (Fig. 11B). More detailed scrutiny of the pattern of
labelling in the retina revealed that it encompassed neurons but
not Mu¨ller cells (Fig. 11C, D, E, F). In the optic nerve, p15INK4B
immunolabelling was associated with the nuclei of glial columns
(Fig. 11 G, H), particularly in the myelinated portion of the nerve.
Figure 5. Representative images of p16INK4A immunolabelling in human and rat ocular tissues. In formalin-fixed, paraffin-embedded
human eyes, no positive labelling for p16INK4A is discernible in the corneal epithelium (A), trabecular meshwork (TM)/Schlemm’s canal (SC) (B), or
retina (C). In formalin-fixed, paraffin-embedded rat eyes, no positive labelling for p16INK4A is discernible in the corneal epithelium (D), retina (E) or
optic nerve (F). Scale bar: A, B, D, F = 15 mm; C, E = 30 mm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
doi:10.1371/journal.pone.0075067.g005
Figure 6. Representative images of p14ARF immunolabelling in human ocular tissues. In formalin-fixed, paraffin-embedded sections of
cervical intraepithelial neoplasia, p14ARF expression is identified, as expected, within nuclear inclusions (A). In formalin-fixed, paraffin-embedded
human eyes, no positive labelling for p14ARF is discernible in the corneal epithelium (B), trabecular meshwork (TM)/Schlemm’s canal (SC) (C), retina
(D), unmyelinated optic nerve (E), or myelinated optic nerve (F). Scale bar = 15 mm. GCL, ganglion cell layer; INL, inner nuclear layer.
doi:10.1371/journal.pone.0075067.g006
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Discussion
In light of previous work defining the importance of gene
products from the 9p21 locus in diseases such as coronary heart
disease [21,22,23], diabetes [21,46], atherosclerosis [26] and
cancer [24,25], the systematically validated discovery that SNPs
from this region are also associated with POAG is of great
significance [7,8,11,12,13,14,15,16,17,18,19,20]. The logical first
step in disseminating the role that such gene products might play
in POAG is an investigation into their expression and localization
within the normal eye; such was the purpose of the current study.
In undertaking this project, we concentrated on both human and
rat ocular tissues. Rodent models of glaucoma are increasingly
used to investigate the pathogenesis of retinal ganglion cell loss;
thus, delineation of the expression patterns in both species permits
a better understanding of the commonality between humans and
rats and the relevance of conducting basic research.
Owing to the absence of suitable tissue from human eyes for
analysis by Western blotting and RT-PCR, these latter techniques
were restricted to the rat. This situation inevitably resulted in the
main focus of the current study being on visualisation of 9p21 gene
products by immunohistochemistry. This is not necessarily a
straightforward task, despite the proliferation of commercially
available antibodies, since biologically meaningful immunohisto-
chemical data can only be obtained if the antibodies in question
are meticulously validated using the methodologies employed by
the researchers. Disturbingly, commercial antibodies often fail
rudimentary tests of specificity [47], which, when combined with
inadequate controls, leads to publication of erroneous results. The
interrelated topics of antibody specificity and appropriate controls
for use with immunohistochemistry have been covered in
numerous reviews and editorials in recent years [47,48,49,50]. A
number of immunohistochemistry controls can be employed, of
which some of the more useful are as follows: (1) Western blot data
showing both that the primary antibody can bind specifically to a
correctly sized antigen and that such a band is observed in tissues
displaying a positive immunohistochemical signal; (2) lack of signal
in tissue from a knockout animal; (3) comparison of results from
separate antibodies raised against different epitopes of the protein;
(4) lack of signal in tissue with a known minimal level of expression
of the molecule; (5) presence of cell-type specific labelling at high
signal-to-background in tissue with known expression of the
molecule; (6) correlation of protein expression with mRNA
expression, for example by in situ hybridization or RT-PCR; (7)
absence of signal when the primary antibody is preincubated with
an excess of the antigen prior to use (preadsorption test). With the
exception of the relevant knockout rats, which we were unable to
obtain for this investigation, we have made use of all of these
controls.
MTAP
MTAP, an enzyme that plays an essential role in the salvage of
cellular adenine and methionine following biosynthesis of poly-
amines, has been shown to be present in all normal mammalian
tissues analysed with particularly high levels of activity described in
the liver and lung [51,52]. Despite the growing interest in the role
of MTAP, the cellular distribution of the protein in normal CNS
tissue, and the eye in particular, has received negligible attention.
Our results show that the levels of MTAP mRNA expression in the
normal rat retina and optic nerve are comparable, each equating
to about 0.3% and 1%, respectively, of the levels of the
housekeeping genes glyceraldehyde 3-phosphate dehydrogenase
and cyclophilin. The MTAP transcript, whilst not abundant, is
expressed at a considerably higher level in the retina than the
transcripts encoding p16INK4A, p15INK4B and p19ARF. As regards
the protein, three commercially available antibodies were tested.
Although each of the antibodies detected recombinant MTAP and
were able to distinguish proteins at the predicted molecular mass
in liver and retina samples using Western blotting, the polyclonal
antibody from Proteintech proved best suited to detection of the
protein in tissue sections. This antibody has previously been
validated for detection of MTAP in malignant pleural mesothe-
lioma [37], gastro-intestinal tumors [53,54] and chordoma [55]
providing further evidence of its specificity. In the anterior
segment of the human eye, positive immunolabelling was evident
in both the corneal epithelium and trabecular meshwork, while in
the retina, MTAP immunoreactivity was principally associated
with astrocytes and Mu¨ller cells. In the rat retina, MTAP appeared
to be associated with astrocytes but not Mu¨ller cells. It is possible
that neuronal cells in the human and rat retina also express
MTAP, but the protein abundance is below the detection limits of
the immunohistochemical assay. Overall, the immunohistochem-
istry, Western blotting and real-time RT-PCR methodologies
provided unambiguous results that correlated satisfactorily.
Further studies should investigate whether MTAP expression in
the trabecular meshwork and in glial cells of the retina and optic
nerve is important in the pathogenesis of POAG.
P16INK4A
P16INK4A is a principle member of the INK4 family of proteins,
which also includes p15INK4B, p18INK4C and p19INK4D, and whose
major function is to inhibit cyclin-dependent kinases (CDKs) and
therefore exert control on the cell cycle (see review by Romagosa
et al. [56]). P16Ink4A itself contributes to regulation of the cell cycle
by binding to CDK4 and CDK6. In the absence or malfunction-
ing of p16Ink4A, these enzymes associate with cyclin-D and
phosphorylate the retinoblastoma protein, ultimately activating
transcription factors of the E2F family and promoting G1/S
transition. Aberrant functioning of p16Ink4A can, therefore, have
profound pathological influences derived from erroneous regula-
tion of the cell cycle and/or entry of the cell into apoptosis [57]. It
is of no surprise, therefore, to find that alterations in physiological
Figure 7. Immunocytochemical localization of p19ARF protein
in cultured, undifferentiated, non-confluent, rodent RGC-5
cells. (A–C) Use of the Santa Cruz antibody (A), shown in relation to
nuclear DAPI counterstaining (B, C), reveals little P19ARF protein labeling
except for some cytoplasmic granules (arrowheads). There is no obvious
nuclear labeling. (D–F) Use of the p19ARF antibody from Upstate,
however, denotes clear nuclear labeling within cells. The positive
labeling appears to be present in nucleolar-like structures within cell
nuclei (as denoted by DAPI-positive staining; arrows). This labeling is
present in approximately 75% of cells. Scale bar = 10 mm.
doi:10.1371/journal.pone.0075067.g007
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expression levels of p16Ink4A are associated with many types of
human disease as well as with aging and senescence [56].
Preliminary data, included within our previous study [7],
indicated high expression of p16INK4A in rat retina. This
conclusion was based on immunohistochemical staining of tissue
sections with antibody clone 2D9A12 (Abnova), which yielded
high signal-to-background nuclear labelling in virtually all retinal
cells. We were, therefore, surprised to discover that the rat retinal
Figure 8. Evaluation of p19ARF antibodies, and p19ARF expression in rat retina and optic nerve. (A) Evaluation of two p19ARF antibodies,
from Upstate and Santa-Cruz (sc), by Western immunoblotting using full length, recombinant rat p19ARF protein (r P19ARF). For each antibody tested,
molecular weight markers were used to determine size of detected gel products (A, C; lane M). Lane 1, 100 ng of r P19ARF; Lane 2, 10 ng rP19ARF.
Single bands of the correct molecular mass are detectable by the Upstate antibody, but not by the Santa Cruz antibody. (B) Rat brain cortex (lane 1),
liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for p19ARF protein with the Upstate and sc antibodies. The Upstate antibody
does not recognize any proteins at the correct molecular mass, but the sc antibody recognises a 19 kD protein in the optic nerve sample. Labelling
for b-actin (house-keeping gene product) is also shown. (C) Further testing of both antibodies against retina (lanes 1–3) and optic nerve (lanes 4–6)
samples obtained from three different rats reveals that the Upstate antibody fails to detect a band at 19 kD in any sample, but detects a protein of
approximately 38 kD in the retinal, and a protein of 48 kD in the optic nerve, samples. The sc antibody recognises a 19 kD protein in each optic nerve
sample but not in the retinal samples. (D) Representative images of p19ARF immunolabelling using the Upstate p19ARF antibody in the rat retina and
optic nerve. No nuclear staining is detectable in cells of the retina or optic nerve; however, robust labelling of axons in the myelinated, but not
unmyelinated, optic nerve is apparent. This is most clearly shown in the image taken of the optic nerve head (ONH). Scale bar = 30 mm. GCL, ganglion
cell layer; INL, inner nuclear layer.
doi:10.1371/journal.pone.0075067.g008
Table 5. Expression of mRNA for p15INK4B in rat tissues.
retina optic nerve brain liver
cyclophilin CT 17.660.1 19.560.2 18.260.1 19.560.2
p15INK4B CT 31.060.3 25.660.1 31.760.1 30.660.4
1DCT 13.360.3 6.060.2 13.560.1 11.160.1
2mRNA level 0.00026361025 0.01860.001 0.00016161025 0.006360.0002
CT, cycle threshold;
1DCT, target CT - cyclophilin CT;
2target mRNA level expressed relative to cyclophilin.
doi:10.1371/journal.pone.0075067.t005
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samples analysed in the present study had minimal expression of
p16INK4A mRNA: the transcript level approximated to 0.001% to
0.008% of the level of the housekeeping cyclophilin, depending on
the primer set used in the real-time PCR assay. The low level of
p16INK4A mRNA in the retina agrees with previous research,
which has shown that p16INK4A mRNA is not expressed at
detectable levels in adult human [7,58] or rodent [59,60,61] CNS.
Although various studies have documented that p16INK4A is a
relatively stable protein, the mismatch between mRNA and
immunohistochemistry clearly needed addressing. To test the
validity of clone 2D9A12, we performed Western blotting and
immunohistochemistry using three further p16INK4A antibodies
that are all reactive in rat and human tissue. Furthermore, we
made use of arguably the definitive positive control tissue for
expression of p16INK4A, namely abnormal cervical tissue. The
diagnostic value of p16INK4A overexpression has been proven in
high risk human papillomavirus infections, in cervical dysplasia
and in various cervical carcinomas [38,39]. The results were clear-
cut: the Santa-Cruz (sc-1661), Proteintech and Sigma antibodies
all detected recombinant p16INK4A on Western blots and yielded
robust immunolabelling in cervical carcinoma tissue sections, but,
no specific p16INK4A immunolabelling was observed in the cornea,
drainage angle, retina or optic nerve of human or rat tissue
sections. These data correlate with the real-time PCR results and
Figure 9. Evaluation of p15INK4B expression by Western immunoblotting. (A, B) Validation of p15INK4B antibody specificity by Western
blotting using GST-tagged, full length, recombinant human p15INK4B (rp15INK4B) and p16INK4A (rp16INK4A) proteins. M, molecular weight markers. (A)
Reactivity of antibody to rp15INK4B, where lane 1, 100ng of rp15INK4B; Lane 2, 10 ng rp15INK4B; Lane 3, 1 ng rp15INK4B P; Lane 4, 100 pg rp15INK4B. Single
bands of the expected molecular weights (for protein incorporating GST-tag) are apparent. (B) Reactivity of antibody to rp16INK4A in order to
determine any non-specific binding to the highly related protein p16INK4A, where lane 1, 100 ng of rp16INK4A; Lane 2, 10 ng rp16INK4A; Lane 3, 1 ng
rp16INK4A; Lane 4, 100 pg rp16INK4A. (C) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for rp15INK4B. A
15 kD protein is detectable in all tissue samples; results plotted on bar graph to show quantitative distribution. (D) Expression of p15INK4B in retinal
(lanes 1–3) and optic nerve (lanes 4–6) samples. Labelling for b-actin (house-keeping gene product) is also shown; results for p15INK4B plotted on bar
graph to show quantitiative distribution, relative to actin levels.
doi:10.1371/journal.pone.0075067.g009
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suggest that p16INK4A is not expressed to any significant degree in
normal human or rat ocular tissues. The results also concur with
previous studies that have investigated p16INK4A expression in
retinoma [62] and retinoblastoma [63]. In both of these studies,
one of which featured Santa-Cruz antibody sc-1661, tumor cells
were typically p16INK4A-positive, but adjacent, healthy retina was
p16INK4A-negative. In contrast, clone 2D9A12 gave unsatisfactory
results when used for Western blotting, less reliably demarcated
p16INK4A overexpression in abnormal cervical cells, and, addi-
tionally elicited robust nuclear labelling of numerous cells in
surrounding healthy cervical tissue in an analagous manner to that
observed in ocular tissue sections. Our study raises serious
Figure 10. Representative images of p15INK4B immunolabelling in human tissues. In formalin-fixed, paraffin-embedded tissue sections,
weak, diffuse p15INK4B immunolabelling of the cervical intraepithelial neoplastic lesion (red asterisk) and robust labelling of a subset of inflammatory
cells in the underlying stroma (arrow) is observed (A). In skin sections, p15INK4B immunoreactivity is associated with cutaneous squamous cells (B,
arrows). In formalin-fixed, paraffin-embedded human eyes, positive labelling for P15INK4B is discernible in the nuclei of cells located in the corneal
epithelium (C) and trabecular meshwork/Schlemm’s canal (D). In the retina, P15INK4B labelling is associated with the nuclei of cells within the GCL and
INL (arrows; E, F). Scale bar: C, F = 15 mm; A, D, E = 30 mm; B= 60 mm. GCL, ganglion cell layer; INL, inner nuclear layer.
doi:10.1371/journal.pone.0075067.g010
Figure 11. Representative images of p15INK4B expression in rat retina and optic nerve. (A) P15INK4B immunoreactivity is associated with
nuclei within the GCL and INL (arrows), the intensity of which is substantially reduced after preadsorption with recombinant P15INK4B protein (B).
Greater magnification images of retinas labelled with the CST antibody (C, E) reveal a pattern of labelling in the INL that encompasses neurons, but
not Mu¨ller cells. For comparative purposes, the distribution of Mu¨ller cells is revealed in adjacent sections using an antibody directed against FGF-2
(D, F). In the optic nerve, labelling is observed within the nuclei of a subset of glial cells. Labelling is stronger in the myelinated portion of the nerve
than in the unmyelinated ONH (black arrow indicates myelination transition zone). This effect is more pronounced in the Dark-Agouti (DA; H) strain of
rat than the Sprague-Dawley strain (SD; G). Scale bar: A, B, G, H= 30 mm; C, D= 15 mm; E, F = 6 mm. GCL, ganglion cell layer; INL, inner nuclear layer;
ONL, outer nuclear layer; FGF-2, fibroblast growth factor-2; ONH, optic nerve head.
doi:10.1371/journal.pone.0075067.g011
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questions about the specificity of Abnova clone 2D9A12. We
might speculate that this antibody cross-reacts with p18INK4C or
p19INK4D, which share significant homology with p16INK4A and
are abundantly expressed in normal adult tissues [59], but further
investigation would be needed to explore this possibility.
P14ARF/P19ARF
Human p14ARF (and the rodent equivalent, p19ARF) is derived
from an alternative reading frame of the p16INK4A gene sequence
[64,65]. Originally thought just to be a tumour-suppressor protein
being co-expressed and therefore functioning in the same manner
as p16INK4A, it was surprising to delineate that p14ARF had its own
distinct but complementary role in the control of cell cycle entry
[66]. It is thought that this protein binds to Mdm2, which
functions to ubiquitinylate the key cellular tumour-suppressor
protein, p53, and therefore mark it for degradation by the
proteasome [67]. When p14ARF is expressed, usually under
conditions of cellular stress, it sequesters Mdm2, allowing p53
levels to rise and activate the latter protein’s functions as a
regulator of DNA damage repair, an abrogator of the cell cycle
and a determinant in the instigation of cellular apoptosis [67].
P14ARF therefore has a key role to play in the cellular response to
stress and is therefore usually found, upon expression, within the
nucleus.
When studying p14ARF in human cancerous cervical tissue
sections, this protein was localized to nuclear inclusions in
epithelial cells by two distinct antibodies (CST and Sigma) in
agreement with the known subcellular localization of this protein
[40]. When applied to human ocular sections, however, no such
labeling was seen in any cells and so we conclude that there was
either no p14ARF expressed in the human eye or that, if present, its
levels were so low as to be undetectable by our methods.
Initially studying p19ARF in rodent tissues, we found significant
mRNA expression in the optic nerve relative to all other tissues
examined. Subsequent analysis of tissues by labeling with two
distinct antibodies (Upstate and Santa Cruz) revealed that, as
expected, both labeled nuclei in immortalized mouse RGC-5 cells,
with the Upstate antibody specifically recognizing nuclear
inclusions which were reminiscent of nucleoli [42]. Western blot
data, however, was inconsistent: the Santa Cruz antibody could
not recognize the recombinant protein, but could detect a 19 kD
protein in rat optic nerve extracts, whereas the Upstate antibody
correctly recognized the recombinant protein, but only revealed a
48 kD protein in brain and optic nerve. When rat ocular sections
were examined, the Upstate antibody revealed strong immunola-
belling in the fibres of the post-laminar optic nerve. We therefore
believe that this antibody was actually recognizing a different
axonal protein, an idea reinforced by the positive detection of a
protein in only brain and optic nerve Western extracts. These
findings thus rendered this antibody as inappropriate for further
study in our studies. Alongside these data, the Santa Cruz
antibody could detect no signal in any ocular cell-type or region
and so no conclusion could be drawn as to its eligibility for further
use. The only definitive conclusion that could be drawn from the
p19ARF studies, therefore, was from the mRNA analyses, which
was that expression within the normal retina is negligible but
within the optic nerve measurably higher.
P15INK4B
Like P16INK4A, p15INK4B is a member of the INK4 family of
tumour-suppressor proteins and therefore also functions as a
CDK4/6 inhibitor [68]. As with other INK4 proteins, interaction
with the target CDK prevents binding of cyclin D and this in turn
blocks activation of G1/S-phase transition, holding the cell in a
pre-divided state [68]. Despite the similarities in the known
binding properties of the INK4 group members, the specific
functions of p15INK4B and the reasons why two structurally and
functionally similar proteins are expressed from a single gene locus
remain unknown. Furthermore, specific functions of p15INK4B are
relatively enigmatic compared with those of p16INK4A. It is now
believed, however, that p15INK4B acts generally as a cellular back-
up for p16INK4A in the case of loss-of-function of the latter [69].
P15INK4B has now been linked to the mechanism of TGFb-
induced cell cycle arrest [68]. This could be of relevance to
glaucoma since this latter growth factor is thought to play a role in
the pathogenesis of optic nerve head damage in this disease [70].
Relatively little is known about the expression patterns and roles
of p15INK4B in healthy mammals, but studies have shown it to be
more widely distributed than p16INK4A [59,60,71]. Our qPCR
results support this generalisation: the levels of p15INK4B mRNA in
the rat retina and brain were broadly similar with, as expected
[43], a somewhat greater amount found in the liver. In all three
tissues, the p15INK4B transcript was at a higher level than that of
p16INK4A. Interestingly, our results also showed that, as was the
case for p19ARF, there is a considerably greater expression of
p15INK4B mRNA in the optic nerve than in the retina, although
there was no significant difference in protein levels in these tissues.
Delineation of p15INK4B protein expression in ocular tissues is
more problematic than for p16INK4A, p19ARF and MTAP, since,
to our knowledge, there is no definitive positive control tissue that
can be utilised and no antibody clone that has been well
characterized. P15INK4B protein expression has been documented
using numerous different antibodies and the protein has been
shown to be localised varyingly in the nucleus and cytoplasm. The
situation is further complicated by the fact that FASTA sequence
comparison of the human p15INK4B and p16INK4A proteins reveals
89.5% similarity, although importantly the N-termini of each
protein retain little identity.
Of the four commercially available antibodies tested in the
current study, two provided unsatisfactory results: (1) the Abcam
p15INK4B polyclonal antibody recognised recombinant p16INK4A
with equal potency to p15INK4B. This non-specific interaction
obviously renders it unsuitable for further use; (2) the Santa-Cruz
antibody (K-18), which has been used in numerous published
studies, and, which was raised against a peptide mapping near the
N-terminus engendering confidence in its specificity, provided us
with expected labelling patterns in abnormal cervix and normal
skin tissue sections. Unexpectedly, however, this antibody cross-
reacted with an abundant 35kD protein in the retina that appears
to be produced by photoreceptor outer segments. The two other
antibodies used: a polyclonal antibody (CST) raised against a
peptide mapping near the N-terminus and a monoclonal antibody
(Neomarkers; clone 15P06) raised against full length p15INK4B,
provided similar patterns of immunolabelling in ocular sections,
namely a nuclear association with cells of the corneal epithelium,
trabecular meshwork, optic nerve and retina, the latter of which
appeared to be restricted to inner retinal neurons. Confidence in
the validity of these results is strengthened by the accompanying
satisfactory Western blotting results, pre-adsorption testing and
labelling patterns in putative positive control tissues.
Conclusion
In conclusion, our results indicate that gene products of the
9p21 locus have defined and restricted patterns of expression in
normal human and rodent ocular tissues. MTAP and p15INK4B
(CDKN2B) are relatively widely expressed, while p16INK4A
(CDKN2A) and p19ARF are essentially undetectable with the
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tools we have used in healthy ocular tissues. The information
provided in this study provide a basis for exploring how expression
of these gene products may alter in glaucoma and other ocular
diseases.
Supporting Information
Figure S1 Evaluation of MTAP antibodies by Western immu-
noblotting. (A) Evaluation of three MTAP antibodies (Cell
Signaling Technology, CST; Santa-Cruz, sc; ProteinTech, PT),
by Western immunoblotting using GST-tagged, full length,
recombinant, human MTAP protein (rMTAP). For each antibody
tested, molecular weight markers were used to determine size of
detected gel products (A; lane M). Lane 1, 100 ng rMTAP; Lane
2, 10 ng rMTAP; Lane 3, 1 ng rMTAP; Lane 4, 100 pg rMTAP.
Single bands of the expected molecular weights (including GST-
tag) are apparent for each of the antibodies. (B) Rat brain cortex
(lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4)
samples probed for MTAP with the CST, sc and PT antibodies.
Each antibody is able to detect a protein at the correct molecular
mass for MTAP in the liver, optic nerve and retinal samples.
Labelling for b-actin (housekeeping gene) and a-tubulin (neuronal
tissue marker) are also shown.
(TIF)
Figure S2 Evaluation of MTAP antibodies in malignant pleural
mesothelioma. In formalin-fixed, paraffin-embedded tissue sec-
tions, the MTAP antibody from Proteintech (PT Ab; A) robustly
labelled inflammatory cells. In comparison, MTAP antibodies
from Cell Signaling Technology (CST Ab; B) and Santa-Cruz (sc
Ab; C) elicited weaker labelling of inflammatory cells (see arrows).
Scale bar = 30 mm.
(TIF)
Figure S3 Evaluation of p16INK4A antibodies, and p16INK4A
expression in rat tissues, by Western immunoblotting. (A)
Evaluation of four p16INK4A antibodies, from ProteinTech (PT),
Sigma, Santa-Cruz (sc) and Abnova, by Western blotting, using
GST-tagged, full length, recombinant, human p16INK4A protein
(rp16INK4A). For each antibody tested, molecular weight markers
were used to determine size of detected gel products (A; lane M).
Lane 1, 100 ng of rp16INK4A; Lane 2, 10 ng rp16INK4A. Single
bands of the expected molecular weights (including GST-tag) are
apparent for each of the tested antibodies except the Abnova one.
(B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and
retina (lane 4) samples probed for p16INK4A protein with the PT,
Sigma, sc and Abnova antibodies. None of the antibodies detect
proteins at the correct molecular mass for p16INK4A in any rat
tissue sample. Labelling for b-actin (house-keeping gene product) is
also shown. (C) The Sigma and PT antibodies were further tested
against retina (lanes 1–3) and optic nerve (lanes 4–6) samples
obtained from three different rats. The presence of p16INK4A
protein is not detectable in any sample.
(TIF)
Figure S4 Evaluation of antibodies directed against p16INK4A in
cervical adenocarcinoma. In formalin-fixed, paraffin-embedded
tissue sections, incubation with either the Santa-Cruz (sc; A),
Proteintech (PT; B) or Sigma (C) antibodies identifies so-called
‘block’ or ‘diffuse’ immunolabelling of ductal tissue with a high
signal-to-background, as compared to adjacent tissue (arrow). The
staining intensity is greatest for the sc Ab and weakest for the
Sigma antibody. The Abnova (D) antibody only inconsistently
labels abnormal tissue and, additionally, produces nuclear
labelling of adjacent tissue (red asterisk). Further examination of
the Abnova antibody in cervical intraepithelial neoplasia reveals
that the pattern of immunolabelling again differs from that
obtained with the sc Ab (E) featuring weaker staining of the
epithelium and robust nuclear localisation of numerous cells
residing in the stromal tissue (F; red asterisk). Scale bar = 30 mm.
(TIF)
Figure S5 Representative images of p16INK4A immunolabelling
in human ocular tissues. In formalin-fixed, paraffin-embedded
human eyes, no positive labelling for p16INK4A is discernible in the
corneal epithelium, trabecular meshwork (TM)/Schlemm’s canal
(SC), or retina, irrespective of whether the Sigma (A–C) OR
Proteintech (D–F) antibody is used. Scale bar: A, B, D, E, G,
H=15 mm; C, F, I = 30 mm. GCL, ganglion cell layer; INL, inner
nuclear layer.
(TIF)
Figure S6 Representative images of p16INK4A immunolabelling
in rat retina and optic nerve. In formalin-fixed, paraffin-embedded
rat retina (A–C) and optic nerve (D–F), no unambiguous, positive
labelling for p16INK4A is discernible either in retina or in the optic
nerve using the Sigma (A, D) or Proteintech (B, E) antibodies. In
contrast, the Abnova antibody robustly labels all cell nuclei within
the eye, as highlighted in the presented images of retina (C) and
optic nerve (F). Scale bar: A–D=30 mm; E–H=15 mm. GCL,
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear
layer.
(TIF)
Figure S7 Representative images of p14ARF immunolabelling
using the antibody from CST. In formalin-fixed, paraffin-
embedded sections of cervical intraepithelial neoplasia, p14ARF
expression is identified within nuclear inclusions (A). In formalin-
fixed, paraffin-embedded human eyes, no positive nuclear
labelling for p14ARF is discernible in the corneal epithelium (B),
trabecular meshwork (TM)/Schlemm’s canal (SC) (C), retina (D),
unmyelinated optic nerve (E), or myelinated optic nerve (F).
However, robust labelling of axons in the myelinated, but not
unmyelinated, optic nerve is apparent. This labelling is likely non-
specific. Scale bar = 15 mm.
(TIF)
Figure S8 Evaluation of P15INK4B antibodies in the rat. (A)
Evaluation of four P15INK4B antibodies, from Cell Signaling
Technology (CST), Neomarkers (Neo), Abcam and Santa-Cruz
(sc), by Western blotting using GST-tagged, full length, recombi-
nant human P15INK4B (rP15INK4B) and P16INK4A (rP16INK4A)
proteins. M, molecular weight markers. Left-hand column,
reactivity of antibodies to rP15INK4B to determine specificity;
right-hand column, reactivity of antibodies to rP16INK4A in order
to determine whether antisera bind non-specifically to related
proteins. Left-hand column: lane 1, 100 ng of rP15INK4B; Lane 2,
10 ng rP15INK4B; Lane 3, 1 ng rP15INK4B P; Lane 4, 100 pg
rP15INK4B. Single bands of the expected molecular weights (for
protein incorporating GST-tag) are apparent for each of the
antibodies, except sc. Right-hand column: lane 1, 100 ng of
rP16INK4A; Lane 2, 10 ng rP16INK4A; Lane 3, 1 ng rP16INK4A;
Lane 4, 100 pg rP16INK4A. Abcam and, to a minor degree, Neo
antibodies show non-specific reactivity with rP16INK4A. (B) Rat
brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina
(lane 4) samples probed for rP15INK4B with CST, Neo, Abcam and
sc antibodies. The CST antibody recognises a 15 kD protein in all
tissue samples but the labeling for the other antibodies is disparate
and variable. (C) Further testing of the sc antibody against
different retina (lanes 1–3) and optic nerve (lanes 4–6) extracts
reveals that the former antibody recognizes a distinct 35 kD
protein in the retina with a labeling pattern which appears
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identical to that shown by the anti-rhodopsin antibody, Ret-P1.
(D) Incubation of rat retina tissue sections with the sc antibody
reveals immunoreactivity to be associated with photoreceptor
outer segments (white arrow). This labelling pattern resembles that
of RET-P1 labelling of rhodopsin (data not shown) and is unlikely
to represent p15INK4B, which is typically localised to the nucleus of
cells.
(TIF)
Figure S9 Evaluation of antibodies directed against p15INK4B in
cervical intraepithelial neoplasia and skin. In formalin-fixed,
paraffin-embedded tissue sections, incubation with either the
CST (A) or Santa-Cruz (B) p15INK4B antibodies results in weak,
diffuse immunolabelling of the cervical intraepithelial neoplastic
lesion (red asterisk) and robust labelling of a subset of
inflammatory cells in the underlying stroma (arrow). In contrast,
incubation with the Abcam (C) p15INK4B antibody yields a pattern
of labelling that more closely resembles that of p16INK4A (D),
namely stronger staining of the CIN and negligible association
with stromal components. In skin sections, the CST (E) and Santa-
Cruz (F) antibodies labelled cutaneous squamous cells (arrows)
Scale bar: A–D=30 mm; E, F= 60 mm.
(TIF)
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